Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human open-label dose-escalation and expansion study of GEN1042 alone and with pembrolizumab in malignant solid tumors
MOH_2023-07-31_012855Phase 2Completed
- Sponsor
- Genmab
- Start
- Jun 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of tecaginlimab in Non-hematologic malignancy, melanoma, non-small cell lung cancer (NSCLC) and 3 more (4 arms), sponsored by Genmab. Primary endpoints: Maximum tolerated dose, Recommended phase 2 dose and 1 more. Started Jun 2023; status: completed.
02
Drugs
tecaginlimab
03
Conditions
Non-hematologic malignancymelanomanon-small cell lung cancer (NSCLC)colorectal cancer (CRC)head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on MOH_2023-07-31_012855.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-31_012855.